Discover the challenges related to the distribution of orphan drugs in Europe and identify key criteria for selecting a suitable partner.
The staggering complexity of launching drugs into a new market can mean that patients in Europe are missing out on potential life-changing treatments developed by US biotechs. Unlike in the US, where it is possible to reach patients anywhere in the country with one license, one language, and one supply chain, in Europe it is necessary to think about meeting the requirements of 27 different countries.
Download this exclusive guide to learn how to navigate the complex European landscape, including takeaways on:
Offered Free by: Sciensus Pharma Services
See All Resources from: Sciensus Pharma Services